Advice
in the absence of a submission from the holder of the marketing authorisation:
zanubrutinib (Brukinsa®) is not recommended for use within NHSScotland.
Indication under review: in combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice229KB (PDF)
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2671
- Indication:
In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 May 2024